23 completed, 6 recruiting, 3 terminated, 3 withdrawn. 38 Phase 2, 14 Phase 1, 1 Phase 3.
Follow Peanut Allergy: new trials by email Literature Review of Peanut Allergy trials Research Report on Peanut Allergy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy Autoclaved peanut oral immunotherapy, Blanched peanut oral immunotherapy - Peanut Allergy | Phase 2 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 57 | 2026-08-01 | 2026-03-03 |
| Efficacy of Tezepelumab in Peanut Oral Immunotherapy Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab - Peanut Allergy | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 62 | 2026-07-27 | 2026-10-22 |
| UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies UKK-0018 - Peanut-Induced Anaphylaxis, Peanut Allergy | Phase 1 / Phase 2 | Recruiting | Ukko Inc | 40 | 2026-02-18 | 2026-10-16 |
| Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants ENP-501, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | N-Fold, LLC | 68 | 2025-12-16 | 2026-04-24 |
| Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) Versus LOw Dose Peanut OIT for Peanut Allergy Peanut Oral Powder [PEANUT POWDER], Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin) - Peanut Allergy | Phase 2 | Withdrawn | Murdoch Childrens Research Institute | 2024-05-01 | 2024-09-19 | |
| Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients Microbial Transplantation Therapy, Antibiotic, Placebo (in place of MTT) - Allergy, Peanut, Peanut Allergy | Phase 2 | Recruiting | Rima Rachid | 37 | 2023-06-08 | 2025-08-24 |
| A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy PVX-108, Placebo - Peanut Allergy, Peanut Hypersensitivity | Phase 2 | Active not recruiting | Aravax Pty Ltd | 95 | 2023-02-09 | 2026-11-02 |
| Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Peanut SLIT-tablet, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | ALK-Abelló A/S | 209 | 2022-09-07 | 2026-05-11 |
| Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy Abatacept, Placebo, Peanut oral immunotherapy - Peanut Allergy | Phase 2 | Completed | Philippe Bégin | 14 | 2022-03-01 | 2024-11-27 |
| Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy Prebiotic, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | University of Chicago | 20 | 2021-11-30 | 2026-03-09 |
| STEP-IT-UP - Peanut Allergy Study for Infants Peanut powder or peanut butter - Peanut Allergy, Food Allergy | Phase 2 | Withdrawn | Johns Hopkins University | 2021-11-01 | 2021-11-17 | |
| Oral Immunotherapy for Peanut Allergic Patients INP20, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | InnoUp Farma S.L. | 50 | 2020-03-11 | 2025-04-30 |
| Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE) Omalizumab, Dupilumab, Placebo for Dupilumab - Hypersensitivity, Food Allergy | Phase 2 | Completed | Stanford University | 130 | 2020-02-05 | 2026-05-29 |
| Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy Peanut Protein, Continued peanut avoidance - Food Allergy, Peanut Allergy | Phase 2 | Completed | Scott Sicherer | 73 | 2019-08-05 | 2025-02-07 |
| VE416 for Treatment of Food Allergy Vancomycin plus VE416 before PNOIT, Vancomycin plus VE416 with PNOIT, Placebo plus VE416 with PNOIT - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | Massachusetts General Hospital | 60 | 2019-06-28 | 2023-10-18 |
| Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy Peanut Immunotherapy - Food Allergy, Peanut Allergy | Phase 1 / Phase 2 | Terminated | University Hospital, Geneva | 12 | 2019-04-01 | 2023-08-28 |
| Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy Dupilumab - Peanut Allergy | Phase 2 | Completed | Regeneron Pharmaceuticals | 25 | 2019-03-12 | 2022-05-19 |
| Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) Dupilumab, Placebo matching dupilumab, AR101 - Peanut Allergy | Phase 2 | Completed | Regeneron Pharmaceuticals | 148 | 2018-10-03 | 2024-02-07 |
| Salvage Peanut Oral Immunotherapy Study Peanut OIT - Peanut Allergy | Phase 1 / Phase 2 | Completed | University of North Carolina, Chapel Hill | 15 | 2018-01-03 | 2023-01-30 |
| Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy Etokimab, Placebo - Peanut Allergy | Phase 2 | Completed | AnaptysBio, Inc. | 20 | 2017-01-26 | 2023-07-27 |
Showing 20 of 38. Sign in to see all of them.
Peanut Hypersensitivity (38) · Food Hypersensitivity (14) · Hypersensitivity (6) · Hypersensitivity, Immediate (2) · Anaphylaxis (1) · Immune System Diseases (1)
Nut and Peanut Hypersensitivity (38) · Immune System Diseases (37) · Hypersensitivity, Immediate (36) · Hypersensitivity (32) · Food Hypersensitivity (24)
Omalizumab (5) · dupilumab (3) · Abatacept (1) · Anti-Bacterial Agents (1) · Capsules (1) · Histamine Antagonists (1) · Immunotherapy (1) · Prebiotics (1) · Probiotics (1) · Ranitidine (1) · Vancomycin (1) · desloratadine (1) · ligelizumab (1) · maltodextrin (1) · tezepelumab (1)
University of North Carolina, Chapel Hill (4) · Johns Hopkins University (3) · Aimmune Therapeutics, Inc. (2) · DBV Technologies (2) · Massachusetts General Hospital (2) · Regeneron Pharmaceuticals (2) · Stanford University (2) · ALK-Abelló A/S (1) · AnaptysBio, Inc. (1) · Aravax Pty Ltd (1) · Assistance Publique - Hôpitaux de Paris (1) · Boston Children's Hospital (1) · Caroline Nilsson (1) · Hamilton Health Sciences Corporation (1) · InnoUp Farma S.L. (1)
United States (26) · Canada (7) · France (4) · Australia (2) · Netherlands (2) · New Zealand (1) · Poland (1) · Spain (1) · Sweden (1) · Switzerland (1)
Wesley Burks, MD (3) · Edwin Kim, MD (2) · Wayne G Shreffler, MD, PhD (2) · Ana Tabar, PhD, MD (1) · Andrew MacGinnitie, MD, PhD (1) · Brian Vickery, MD (1) · Bruce Randazzo, MD (1) · Caroline Nilsson, MD, PhD (1) · Christina E Ciaccio, MD (1) · Christophe Dupont, MD, PhD (1) · Corinne Keet (1) · Corinne Keet, MD, MS (1) · Edwin H Kim, M.D., M.S. (1)
PMID 38814736, PMID 30978404, PMID 34389504, PMID 25925398, PMID 27883239, PMID 29136445, PMID 29700872, PMID 29709643, PMID 31329313, PMID 31522849, PMID 31723064, PMID 32434067, PMID 32783912, PMID 33463542, PMID 34669990, PMID 34755130, PMID 34813505, PMID 39673367, PMID 39673452, PMID 39928078, PMID 41488220, PMID 41615410, PMID 42685867
2018 (2), R01AT004435 (2), U19AI070345 (1), U19AI095261 (1), U19AI104209 (1), U19AI136053 (1)